{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:37:26Z","timestamp":1783039046747,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.043","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T08:43:01Z","timestamp":1691138581000},"page":"5655-5661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-1614","authenticated-orcid":false,"given":"L.","family":"Moscara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5930","authenticated-orcid":false,"given":"V.","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-6246","authenticated-orcid":false,"given":"A.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Violante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-0210","authenticated-orcid":false,"given":"S.","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3279-0196","authenticated-orcid":false,"given":"P.","family":"Stefanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.07.043_b0005","unstructured":"World Health Organization. Interim statement on booster doses for COVID-19 vaccination. 04 October 2021. Available online at: https:\/\/www.who.int\/news\/item\/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination."},{"key":"10.1016\/j.vaccine.2023.07.043_b0010","unstructured":"European Centre for Disease Prevention and Control. Interim public health considerations for the provision of additional COVID-19 vaccine doses, 1 September 2021. Stockholm: ECDC; 2021."},{"key":"10.1016\/j.vaccine.2023.07.043_b0015","unstructured":"Direzione Generale della Prevenzione Sanitaria. Circolare del Ministero della Salute n. 45886 dell\u20198 ottobre 2021. Aggiornamento indicazioni sulla somministrazione di dosi addizionali e di dosi \u201cbooster\u201d nell\u2019ambito della campagna di vaccinazione anti-SARS-CoV-2\/COVID-19."},{"key":"10.1016\/j.vaccine.2023.07.043_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2021.110793","article-title":"Large-scale IgM and IgG SARS-CoV-2 serological screening among healthcare workers with a low infection prevalence based on nasopharyngeal swab tests in an Italian university hospital: perspectives for public health","volume":"195","author":"Vimercati","year":"2021","journal-title":"Environ Res"},{"key":"10.1016\/j.vaccine.2023.07.043_b0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhin.2021.03.016","article-title":"Rapid decrease of SARS-CoV-2 circulation in a large Italian hospital six weeks after the start of the immunization program","volume":"112","author":"Stefanizzi","year":"2021","journal-title":"J Hosp Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.043_b0030","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/21645515.2017.1348442","article-title":"Influenza vaccination in healthcare workers: a comprehensive critical appraisal of the literature","volume":"14","author":"Dini","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.043_b0035","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1080\/21645515.2021.1999712","article-title":"Could mandatory vaccination increase coverage in health-care Workers? The experience of Bari Policlinico General Hospital","volume":"17","author":"Di Lorenzo","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.07.043_b0040","unstructured":"World Health Organization. Coadministration of seasonal inactivated influenza and COVID-19 vaccines: Interim guidance. 21 October 2021. WHO Reference Number: WHO\/2019-nCoV\/SAGE\/Vaccines_coadministration\/Influenza\/2021.1."},{"key":"10.1016\/j.vaccine.2023.07.043_b0045","unstructured":"Direzione Generale della Prevenzione Sanitaria. Circolare del Ministero della Salute n. 44591 del 2 ottobre 2021. Intervallo temporale tra la somministrazione dei vaccini anti-SARS-CoV-2\/COVID-19 e altri vaccini."},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.043_b0050","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1080\/21645515.2019.1625645","article-title":"Influenza vaccination in health-care workers: an evaluation of an on-site vaccination strategy to increase vaccination uptake in HCWs of a South Italy Hospital","volume":"15","author":"Vimercati","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.043_b0055","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00431-007-0506-z","volume":"166","author":"Zepp","year":"2007","journal-title":"Eur J Pediatr"},{"issue":"22","key":"10.1016\/j.vaccine.2023.07.043_b0060","article-title":"BNT162b2 mRNA vaccine interference with co-administration of Tdap vaccine","volume":"25","author":"Chilimuri","year":"2021","journal-title":"Am J Case Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.043_b0065","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1080\/21645515.2019.1704124","article-title":"Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospective study in Apulia region (ITALY), 2009-2017","volume":"16","author":"Stefanizzi","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.07.043_b0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijid.2020.10.103","article-title":"Safety and immunogenicity of co-administration of meningococcal type A and measles\u2013rubella vaccines with typhoid conjugate vaccine in children aged 15\u201323 months in Burkina Faso","volume":"102","author":"Sirima","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"23","key":"10.1016\/j.vaccine.2023.07.043_b0075","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.vaccine.2013.12.037","article-title":"Systematic review of human papillomavirus vaccine coadministration","volume":"32","author":"Noronha","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.043_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021\u201322 influenza season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.043_b0085","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1993039","article-title":"Two years of on-site influenza vaccination strategy in an Italian university hospital: main results and lessons learned","volume":"18","author":"Bianchi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.07.043_b0090","unstructured":"European Parliament. Directive 2010\/84\/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001\/83\/EC on the Community code relating to medicinal products for human use. Off J Eur Union. 2010 Dec 31."},{"key":"10.1016\/j.vaccine.2023.07.043_b0095","unstructured":"CIOMS\/WHO. Definition and application of terms for vaccine pharmacovigilance. Report of CIOMS\/WHO working group on vaccine pharmacovigilance; 2012."},{"key":"10.1016\/j.vaccine.2023.07.043_b0100","unstructured":"AIFA - Gruppo di Lavoro sull'analisi dei segnali dei vaccini. Guida alla valutazione delle reazioni avverse osservabili dopo vaccinazione; 2016. Available online at http:\/\/www.aifa.gov.it\/sites\/default\/files\/Guida_valutazione_reazioni_avverse_osservabili_dopo_vaccinazione_2.pdf. Last accessed on July 27th, 2022."},{"key":"10.1016\/j.vaccine.2023.07.043_b0105","unstructured":"European Medicines Agency. Important medical event terms list version (MedDRA) - version 24.0. Available online at https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/eudravigilance-system-overview. Last accessed on July 27th, 2022."},{"issue":"19","key":"10.1016\/j.vaccine.2023.07.043_b0110","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2023.07.043_b0115","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.043_b0120","article-title":"Post-marketing active surveillance of adverse reactions following influenza cell-based quadrivalent vaccine: an Italian prospective observational study","volume":"9","author":"Stefanizzi","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.043_b0125","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40265-019-01176-z","article-title":"Cell-based quadrivalent inactivated influenza virus vaccine (Flucelvax\u00ae Tetra\/Flucelvax Quadrivalent\u00ae): a review in the prevention of influenza","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.vaccine.2023.07.043_b0130","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1080\/21645515.2016.1182270","article-title":"Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a Phase III, double-blind, multicenter, randomized, non-inferiority study","volume":"12","author":"Bart","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.07.043_b0135","unstructured":"EMA. Flucelvax Tetra: EPAR - product information. First published 19 Oct 2018. Last updated 22 Feb 2022. Available online at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/flucelvax-tetra-epar-product-information_en.pdf. Last accessed on July 28th, 2022."},{"key":"10.1016\/j.vaccine.2023.07.043_b0140","unstructured":"EMA. Comirnaty: EPAR - product information. First published 12 Jan 2021. Last updated 06 May 2022. Available online at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf. Last accessed on July 28th, 2022."},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.043_b0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.043_b0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.043_b0155","article-title":"Adverse events following measles-mumps-rubella-varicella vaccination and the case of seizures: a post marketing active surveillance in Puglia Italian Region, 2017\u20132018","volume":"7","author":"Stefanizzi","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.043_b0160","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1590\/S0080-623420140000400023","article-title":"Causes for the underreporting of adverse drug events by health professionals: a systematic review","volume":"48","author":"Varallo","year":"2014","journal-title":"Rev Esc Enferm USP"},{"key":"10.1016\/j.vaccine.2023.07.043_b0165","first-page":"154","article-title":"Systematic use of causality assessment in AEFI surveillance: a 2013\u20132016 pilot study in Puglia","volume":"12","author":"Stefanizzi","year":"2017","journal-title":"EBMJ"},{"issue":"51","key":"10.1016\/j.vaccine.2023.07.043_b0170","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1016\/j.vaccine.2014.08.090","article-title":"Are influenza-associated morbidity and mortality estimates for those \u226565 in statistical databases accurate, and an appropriate test of influenza vaccine effectiveness?","volume":"32","author":"Thomas","year":"2014","journal-title":"Vaccine"},{"issue":"10127","key":"10.1016\/j.vaccine.2023.07.043_b0175","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.043_b0180","doi-asserted-by":"crossref","DOI":"10.1186\/s12976-020-00129-4","article-title":"Quantifying the annual incidence and underestimation of seasonal influenza: a modelling approach","volume":"17","author":"McCarthy","year":"2020","journal-title":"Theor Biol Med Model"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.043_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10081193","article-title":"SARS-CoV-2 breakthrough infections: incidence and risk factors in a large European multicentric cohort of health workers","volume":"10","author":"Porru","year":"2022","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.043_b0190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","article-title":"Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022","volume":"11","author":"Wu","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.vaccine.2023.07.043_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9101143","article-title":"BNT162b2 mRNA COVID-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection and symptomatic disease in five-month follow-up: a retrospective cohort study","volume":"9","author":"Bianchi","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.043_bib196","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2011652","article-title":"Acceptability of the third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: preliminary data in a sample of Italian HCWs","volume":"18","author":"Stefanizzi","year":"2022","journal-title":"Hum Vaccin Immunother."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:31:38Z","timestamp":1759404698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23008745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X23008745"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}